<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sandu Pharmaceuticals has filed an initial disclosure confirming it does not qualify as a 'Large Corporate' under SEBI regulations as of March 31, 2026. The filing is pursuant to SEBI circular dated October 19, 2023, which mandates Large Corporates to make specified disclosures regarding debt issuance. The company has submitted the required format (Annexure I) even though it does not meet the criteria. The disclosure shows zero outstanding borrowings as of March 31, 2026, and no credit rating is applicable. Both the Company Secretary and CFO have signed the confirmation. This is a routine regulatory compliance filing.
No direct impact on shareholders. This filing simply confirms the company's small size and exclusion from Large Corporate regulations. The zero borrowings position is neutral to slightly positive, indicating the company is not carrying debt that would require enhanced disclosure under SEBI norms.